|
Kelly Stefano Cole, PhD
|
Associate Director, RBL
Assistant Professor
Immunology
9014 BST3
3501 Fifth Avenue
Pittsburgh, Pennsylvania 15261
Curriculum Vitae
FRIP Database
PubMed Publications
Phone: (412) 648-8583
Fax: (412) 624-4440
E-mail: stefcole@cvr.pitt.edu
Webpage: http://www.cvr.pitt.edu/personnel/view.asp?uid=stefcole
|
|
|
|
Biography
Dr. Cole is an Assistant Professor in Immunology and the Associate Director of the Regional Biocontainment Laboratory. She received her Ph.D. in Immunology in 1994 from the University of Pennsylvania. She came to Pittsburgh in July 1994 as a Postdoctoral Research Associate in the laboratory of Dr. Ronald Montelaro. Her research interest is in defining mechanisms of antibody-mediated neutralization of HIV/SIV and influenza viruses, and understanding the effects of both acute and chronic virus infection on the B cell compartment in vivo.
|
|
Research
Our research focuses on understanding the role of humoral immune responses involved in HIV-1 and the closely related SIV infection and vaccination. We are interested in defining the mechanisms involved in antibody-mediated virus neutralization in vitro, evaluating the effects of variation on virus neutralization in vitro and in vivo, and determining the role of neutralizing antibody in the control of infection and disease progression in vivo. For these studies, we have recently focused our efforts on the real-time binding of virus-specific antibody to envelope antigens using biosensor analyses, and recently have turned to defining the specific envelope determinants involved in antibody binding. Ultimately, our goal is to apply similar neutralization studies of HIV-1 to vaccinated and infected patients. A second major goal of the lab is to characterize the protective immune responses to experimental infection and vaccination in the SIV/monkey model system as a basis for the development and evaluation of effective AIDS vaccines. We are interested in the development of novel assays to characterize the maturation of antibody responses to SIV and HIV-1 envelope proteins, the evaluation of antibody responses elicited by diverse vaccine strategies as correlates of protection, and the application of biochemical and molecular approaches to identify functional and antigenic determinants of these envelope proteins. We are interested in the application of these studies to other viral infections. Recently, we have been focusing our efforts on characterizing the maturation of B cell responses to both acute and chronic stages of virus infection, and to studies involving characterization of the immunogenic and protective immune responses elicited by modified HIV-1 envelope vaccines using a DNA prime, virus-like particle boost regimen in both small animal and nonhuman primate models.
|
|
Selected Publications
- Cole KS , Landucci G., Grieser HJ, Steckbeck JD, Forthal DN. Rhesus monoclonal antibodies identify epitopes in SIV gp120 that mediate antibody-dependent cell-mediated virus inhibition independent of virus neutralization. J Virol 2006; (Submitted).
- Milush JM, Cole KS, Schmidt K, Durudas A, Pandrea I, Sodora DL. Mucosal innate immune response associated with a timely humoral immune response and slower disease progression after oral transmission of simian immunodeficiency virus to rhesus macaques. J Virol 2007; 81: 6175-6186.
- Steckbeck JD and Cole KS. Dissecting the humoral immune response to simian immunodeficiency virus: mechanisms of antibody-mediated virus neutralization. Imm Res 2006;36:51-60.
- McBurney SP, Young KR, Nwaigwe CI, Soloff AC, Cole KS, Ross TM. Lentivirus-like particles without reverse transcriptase elicit efficient immune responses. Curr HIV Res 2006;4:475-84.
- Steckbeck JD, Grieser HJ, Sturgeon TJ, Taber R, Chow A, Bruno J, Murphey-Corb M, Montelaro RC, Cole, KS. Dynamic evolution of antibody populations in a rhesus macaque infected with attenuated simian immunodefiency virus identified by surface plasmon resonance. J Med Primatol 2006; 35:248-260.
- Forthal DN, Landucci G, Cole KS, Becerra JC, Marthas M, Van Rompay K. Rhesus macaque polyclonal and monoclonal antibodies inhibit simian immunodeficiency virus (SIV) in the presence of human or autologous rhesus effector cells. J Virol 2006; J. Virol. 2006; 80:9217-9225.
- Steckbeck JD, Orlov I, Miller K, Chow A, Bruno J, Grieser HJ, Robinson JE, Montelaro RC, Cole KS. Kinetic rates of antibody binding correlate with neutralization sensitivity to simian immunodeficiency virus. J Virol. 2005; 79:12311-12320.
- Cole KS , Steckbeck JD, Rowles JL, Czajak SC, Desrosiers RC, Montelaro RC. Removal of N-linked glycosylation sites in the V1 region of SIV gp120 results in redirection of B-cell responses to V3. J Virol 2004, 78:1525-1539.
- Cole KS , Alvarez M, Elliott DH, Lam H, Rowles JL, Clements JE, Murphey-Corb M, Montelaro RC, Robinson JE. Rhesus monoclonal antibodies to simian immunodeficiency virus define nine binding domains on the surface envelope glycoprotein. Virology 200 1; 290:59-73.
- Cole KS , Paliotti MJ, Robinson JE, Montelaro RC. Maturation of envelope-specific antibody responses to linear determinants in monkeys inoculated with attenuated SIV. J Med Primatol 2000; 29:220-230
|
|
